Please enable JavaScript to continue using this application.

Compare $AVTX vs $SLDB | Chartloom

Compare

$AVTX vs $SLDB

Avalo Therapeutics Inc · Solid Biosciences Inc

AVTX

Avalo Therapeutics Inc

SLDB

Solid Biosciences Inc

Compare $AVTX vs $SLDB

Comparing Avalo Therapeutics Inc and Solid Biosciences Inc

AVTXAvalo Therapeutics Inc

SLDBSolid Biosciences Inc

AVTXAvalo Therapeutics Inc

Market cap

$722M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-86.6%

YTD performance

-19.8%

52W performance

-4.0%

FCF yield

-9.5%

SLDBSolid Biosciences Inc

Market cap

$676M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

26.1%

52W performance

8.9%

FCF yield

-27.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVTX

SLDB

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

SLDB

Solid Biosciences Inc

Market Cap

AVTX$722M

SLDB$676M

Enterprise Value

AVTX$639M

SLDB$517M

Price

AVTX$13.65

SLDB$6.87

P/E Ratio

AVTXN/A

SLDBN/A

P/S Ratio

AVTX12,238.73x

SLDB49.66x

EV/Sales

AVTX10,825.47x

SLDB38.88x

EV/EBITDA

AVTX0.00x

SLDB0.00x

P/B Ratio

AVTX1.79x

SLDB1.96x

P/FCF Ratio

AVTXN/A

SLDBN/A

EV/FCF

AVTX-9.35x

SLDB-2.75x

PEG Ratio

AVTXN/A

SLDBN/A

Forward P/E (NTM)

AVTXN/A

SLDBN/A

Forward P/S (NTM)

AVTXN/A

SLDBN/A

Revenue (TTM)

AVTX$59K

SLDB$0

Revenue Growth (YoY)

AVTX-86.6%

SLDBN/A

Forward Rev Growth

AVTX1345.1%

SLDB822.7%

Gross Margin (TTM)

AVTX242.2%

SLDB0.0%

Operating Margin (TTM)

AVTX0.0%

SLDB0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

SLDB0.0%

Net Margin (TTM)

AVTX-170055.9%

SLDB0.0%

FCF Margin (TTM)

AVTX-115745.8%

SLDBN/A

Net Income (TTM)

AVTX$-100M

SLDB$-207M

FCF (TTM)

AVTX$-68M

SLDB$-188M

EPS (TTM)

AVTX-$2.30

SLDB-$1.44

ROE (TTM)

AVTX-5803.0%

SLDB-7228.0%

ROA (TTM)

AVTX-4822.0%

SLDB-6137.0%

ROIC (TTM)

AVTX-5729.0%

SLDB-7226.0%

Cash

AVTX$85M

SLDB$159M

Debt

AVTX$2M

SLDB$0

Net Cash/Debt

AVTX$83M

SLDB$159M

Current Ratio (TTM)

AVTX19.31x

SLDB13.82x

Quick Ratio (TTM)

AVTX18.95x

SLDB13.24x

Debt/Equity (TTM)

AVTX0.00x

SLDB0.00x

Debt/Assets (TTM)

AVTX0.0%

SLDB0.0%

Interest Coverage (TTM)

AVTXN/A

SLDBN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

SLDB0.00x

Beta

AVTX0.62

SLDB2.60

52W Performance

AVTX-4.0%

SLDB8.9%

YTD Performance

AVTX-19.8%

SLDB26.1%

% from 52W High

AVTX-43.8%

SLDB-40.0%

% from 52W Low

AVTX9.1%

SLDB81.3%

Asset Turnover (TTM)

AVTX0.00x

SLDB0.07x

FCF Yield (TTM)

AVTX-9.5%

SLDB-27.8%

Earnings Yield (TTM)

AVTX-13.9%

SLDB-30.6%

Dividend Yield (TTM)

AVTXN/A

SLDBN/A

Rule of 40

AVTX-115,832.4

SLDB0.0

EV/GP/RG

AVTX1.31

SLDBN/A

Ticker research

View AVTX research View SLDB research

Metric	AVTX Avalo Therapeutics Inc	SLDB Solid Biosciences Inc
Market & Valuation
Market Cap	$722M	$676M
Enterprise Value	$639M	$517M
Price	$13.65	$6.87
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	49.66x
EV/Sales	10,825.47x	38.88x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	1.96x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-2.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$59K	$0
Revenue Growth (YoY)	-86.6%	N/A
Forward Rev Growth	1345.1%	822.7%
Profitability
Gross Margin (TTM)	242.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	0.0%
Net Margin (TTM)	-170055.9%	0.0%
FCF Margin (TTM)	-115745.8%	N/A
Net Income (TTM)	$-100M	$-207M
FCF (TTM)	$-68M	$-188M
EPS (TTM)	-$2.30	-$1.44
ROE (TTM)	-5803.0%	-7228.0%
ROA (TTM)	-4822.0%	-6137.0%
ROIC (TTM)	-5729.0%	-7226.0%
Financial Health
Cash	$85M	$159M
Debt	$2M	$0
Net Cash/Debt	$83M	$159M
Current Ratio (TTM)	19.31x	13.82x
Quick Ratio (TTM)	18.95x	13.24x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	2.60
52W Performance	-4.0%	8.9%
YTD Performance	-19.8%	26.1%
% from 52W High	-43.8%	-40.0%
% from 52W Low	9.1%	81.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	-9.5%	-27.8%
Earnings Yield (TTM)	-13.9%	-30.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	0.0
EV/GP/RG	1.31	N/A
Ticker research	View AVTX research	View SLDB research

Valuation

P/S Ratio

SLDB

49.66x

AVTX

12,238.73x

EV/FCF

AVTX

-9.35x

SLDB

-2.75x

Growth & revenue

Revenue Growth TTM

AVTX

-86.6%

Forward Revenue Growth

AVTX

1345.1%

SLDB

822.7%

Profitability & performance

Gross Margin

AVTX

242.2%

SLDB

0.0%

ROE

AVTX

-5803.0%

SLDB

-7228.0%

FCF Yield %

AVTX

-9.5%

SLDB

-27.8%

52-Week Performance

SLDB

8.9%

AVTX

-4.0%

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

SLDB

Solid Biosciences Inc

Market Cap

AVTX$722M

SLDB$676M

Enterprise Value

AVTX$639M

SLDB$517M

Price

AVTX$13.65

SLDB$6.87

P/E Ratio

AVTXN/A

SLDBN/A

P/S Ratio

AVTX12,238.73x

SLDB49.66x

EV/Sales

AVTX10,825.47x

SLDB38.88x

EV/EBITDA

AVTX0.00x

SLDB0.00x

P/B Ratio

AVTX1.79x

SLDB1.96x

P/FCF Ratio

AVTXN/A

SLDBN/A

EV/FCF

AVTX-9.35x

SLDB-2.75x

PEG Ratio

AVTXN/A

SLDBN/A

Forward P/E (NTM)

AVTXN/A

SLDBN/A

Forward P/S (NTM)

AVTXN/A

SLDBN/A

Revenue (TTM)

AVTX$59K

SLDB$0

Revenue Growth (YoY)

AVTX-86.6%

SLDBN/A

Forward Rev Growth

AVTX1345.1%

SLDB822.7%

Gross Margin (TTM)

AVTX242.2%

SLDB0.0%

Operating Margin (TTM)

AVTX0.0%

SLDB0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

SLDB0.0%

Net Margin (TTM)

AVTX-170055.9%

SLDB0.0%

FCF Margin (TTM)

AVTX-115745.8%

SLDBN/A

Net Income (TTM)

AVTX$-100M

SLDB$-207M

FCF (TTM)

AVTX$-68M

SLDB$-188M

EPS (TTM)

AVTX-$2.30

SLDB-$1.44

ROE (TTM)

AVTX-5803.0%

SLDB-7228.0%

ROA (TTM)

AVTX-4822.0%

SLDB-6137.0%

ROIC (TTM)

AVTX-5729.0%

SLDB-7226.0%

Cash

AVTX$85M

SLDB$159M

Debt

AVTX$2M

SLDB$0

Net Cash/Debt

AVTX$83M

SLDB$159M

Current Ratio (TTM)

AVTX19.31x

SLDB13.82x

Quick Ratio (TTM)

AVTX18.95x

SLDB13.24x

Debt/Equity (TTM)

AVTX0.00x

SLDB0.00x

Debt/Assets (TTM)

AVTX0.0%

SLDB0.0%

Interest Coverage (TTM)

AVTXN/A

SLDBN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

SLDB0.00x

Beta

AVTX0.62

SLDB2.60

52W Performance

AVTX-4.0%

SLDB8.9%

YTD Performance

AVTX-19.8%

SLDB26.1%

% from 52W High

AVTX-43.8%

SLDB-40.0%

% from 52W Low

AVTX9.1%

SLDB81.3%

Asset Turnover (TTM)

AVTX0.00x

SLDB0.07x

FCF Yield (TTM)

AVTX-9.5%

SLDB-27.8%

Earnings Yield (TTM)

AVTX-13.9%

SLDB-30.6%

Dividend Yield (TTM)

AVTXN/A

SLDBN/A

Rule of 40

AVTX-115,832.4

SLDB0.0

EV/GP/RG

AVTX1.31

SLDBN/A

Ticker research

View AVTX research View SLDB research

Metric	AVTX Avalo Therapeutics Inc	SLDB Solid Biosciences Inc
Market & Valuation
Market Cap	$722M	$676M
Enterprise Value	$639M	$517M
Price	$13.65	$6.87
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	49.66x
EV/Sales	10,825.47x	38.88x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	1.96x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-2.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$59K	$0
Revenue Growth (YoY)	-86.6%	N/A
Forward Rev Growth	1345.1%	822.7%
Profitability
Gross Margin (TTM)	242.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	0.0%
Net Margin (TTM)	-170055.9%	0.0%
FCF Margin (TTM)	-115745.8%	N/A
Net Income (TTM)	$-100M	$-207M
FCF (TTM)	$-68M	$-188M
EPS (TTM)	-$2.30	-$1.44
ROE (TTM)	-5803.0%	-7228.0%
ROA (TTM)	-4822.0%	-6137.0%
ROIC (TTM)	-5729.0%	-7226.0%
Financial Health
Cash	$85M	$159M
Debt	$2M	$0
Net Cash/Debt	$83M	$159M
Current Ratio (TTM)	19.31x	13.82x
Quick Ratio (TTM)	18.95x	13.24x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	2.60
52W Performance	-4.0%	8.9%
YTD Performance	-19.8%	26.1%
% from 52W High	-43.8%	-40.0%
% from 52W Low	9.1%	81.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	-9.5%	-27.8%
Earnings Yield (TTM)	-13.9%	-30.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	0.0
EV/GP/RG	1.31	N/A
Ticker research	View AVTX research	View SLDB research